SwedenSweden

Medivir Selects Drug Candidate and Wins EU Patent

08.05.2004

Huddinge - Swedish Medivir AB and Peptimmune Inc., Cambridge (USA), have jointly selected an orally active, small molecule inhibitor of the protease enzyme Cathepsin S as a candidate drug (see EuroBiotechNews 4/04). The Cathepsin S programme is a joint-venture between the two companies with a strong research and intellectual property position in the autoimmune and inflammatory disease areas. The programme includes a license to the intellectual property rights to Cathepsin S as a therapeutic target from the Massachusetts Institute of Technology and issued and pending patents in the United States, Europe and rest of world.
Cathepsin S plays a significant role in the activation of immune responses. Potential clinical applications of the inhibitors include controlling the initiation or progression of immune system disorders such as multiple sclerosis, rheumatoid arthritis, allergic asthma or pain. The project now enters the pre-clinical development with the aim to file an Investigational New Drug application (IND) and to enter clinical phase I trials.
Also in late March the European Patent Office has granted a patent on Medivir AB's herpes project ME-609. The company currently has operational responsibility for development of the project and preparations towards phase III studies are ongoing. Parallel to this, Medivir is seeking a partnership or joint venture for this advanced project. The patent (EP0909498B1) that has been granted in all the EU-15 countries, Switzerland and the new EU member states Slovenia, Liechtenstein, Latvia and Lithuania, extends to 2016. It covers all topical pharmaceuticals that include the antiviral acyclovir and the glucocorticoid hydrocortisone and also claims the use of such products in the treatment of herpes infections.

SwedenSweden

14.04.2011

Stockholm – Swedish Orphan Biovitrum AB (SOBI) has reported weak results for 2010. The company’s net income declined by 7.7% to SEK1.9bn, with losses for the period totalling up to SEK104m. SOBI spokesmen said that several...

SwedenSweden

06.04.2011

Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR...

SwedenSweden

08.02.2011

Stockholm – At the end of last year, the first European patient was treated with Ruconest – a recombinant C1 esterase inhibitor for the treatment of hereditary acute angioedema attacks developed by the Dutch Pharming Group NV and...

SwedenSweden

10.12.2010

Lund/Jerusalem – Active Biotech’s oral small molecule immunomodulator laquinimod (ABR-215062) has reached the primary endpoint of statistically significant reduction in annualized relapse rate compared to placebo, according to...

SwedenSweden

04.11.2010

Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the...

SwedenSweden

25.10.2010

Stockholm - Swedish researchers have unravelled the three-dimensional structure of the egg receptor, paving the way for new treatments of infertility and novel contraceptives. The team headed by Luca Jovine at Karolinska...

SwedenSweden

16.09.2010

Uppsala – Orexo AB has announced a bold new strategy. The company listed on the Stockholm stock exchange intends to develop and commercialise its own products from now on rather than out-licensing them to international partners....

SwedenSweden

15.09.2010

Linköping – In the first clinical study of its kind, Swedish researchers have proven that biosynthetic corneas can offer a real alternative to rare human replacement corneas. In a process developed by Per Fagerholm and May...

Displaying results 21 to 30 out of 182

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/2/article/medivir-selects-drug-candidate-and-wins-eu-patent.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014


Current issue

All issues

Product of the week

Products